Governance Dynamics During M&A Transactions
For most of a clinical-stage company's life, the board and management are pointed at the same thing. Advance the science, hit the milestones, raise the next round, build the asset. Interests are broadly aligned, and where they differ the differences are manageable. Then an acquirer appears — solicited or not — and something changes character. The company stops being an enterprise to build and becomes an asset to divide. And the moment value is being divided rather than created, the interests that were aligned for years begin to diverge.
This is what makes M&A governance distinct. It is not simply a bigger version of the transaction oversight a board does routinely. It is a situation in which the people around the table, all of whom may have served the company faithfully, suddenly have materially different stakes in the outcome — and in which the board's own conduct, not just the deal terms, becomes the thing that will be judged afterward.
This article is about governing that transition: what actually changes when a sale process begins, which conflicts surface, and why the integrity of the process is not a legal formality but the substance of what the board is responsible for.
What Changes When the Company Is in Play
The first thing to understand is that the board's frame of reference shifts. Through the building years, directors are stewards of a long-term enterprise, weighing decisions against a future that extends well beyond any single transaction. In a sale of control, that horizon collapses. There is no next year in which a mistake can be recovered. The decision is terminal for the shareholders whose interests the board represents, and it is judged as such.
Under Delaware law — which governs a large share of these companies — a board facing a sale of control of a traditional corporation is expected to seek the best value reasonably available for stockholders, and courts apply a heightened level of scrutiny to how the board conducted itself. Directors retain real discretion over how to run the process; the standard is not a formula. But the deferential posture courts ordinarily take toward board decisions is not automatic here, and whether the board's conduct is reviewed deferentially or subjected to far more demanding scrutiny turns substantially on how conflicts were handled and how the process was run.
For a board, the practical implication is worth stating plainly: in a sale, the process is not paperwork around the decision. The process is a large part of what the board will be evaluated on. A defensible price reached through a compromised process is a genuine exposure, and a board that treats process discipline as lawyer-driven overhead has misread its own position.
(This article is governance guidance, not legal advice. The applicable standards vary by jurisdiction, entity form, and circumstance, and any board in a live transaction should be working with qualified transaction counsel.)
The Conflicts That Surface
The reason process discipline matters so much is that a sale reliably activates conflicts that lay dormant while the company was building. Naming them precisely is the first act of governing them, and identifying them early — before the process gains momentum — is the single most valuable procedural step a board can take.
The investor director whose fund has its own clock. Venture and institutional investors sit on most clinical-stage boards, and their designees are usually capable and committed directors. But a fund has a life, a vintage, portfolio-level considerations, and its own liquidity needs, and those can argue for selling now, or for a particular deal structure, in ways that do not track what is best for shareholders generally. This is not misconduct; it is a structural divergence between a fiduciary obligation to the company's stockholders and an economic obligation to a fund's limited partners. It becomes acute in exactly the moment a sale is on the table.
Preferred and common are not in the same position. This is the conflict most specific to venture-backed biopharma and the one boards most often handle poorly. Where preferred stock carries liquidation preferences, a given sale price can be excellent for preferred holders and worth very little to common holders — including the founders and employees whose equity is the reason they stayed. At certain valuations, the two constituencies do not merely disagree about the deal; they can rationally want different outcomes entirely, with preferred holders indifferent between two prices that are the difference between something and nothing for common. Directors designated by preferred holders sit at that table. A board that does not surface this explicitly, and take advice on how to handle it, is carrying a serious and well-known risk.
Management's retention and change-of-control economics. Acquirers frequently want to retain key executives, and change-of-control provisions, retention packages, and go-forward roles are ordinary features of these transactions. They are also a direct financial interest that management acquires in a particular deal closing with a particular buyer. The CEO negotiating the transaction may simultaneously be negotiating their own future employment and payout. This does not make management untrustworthy, but it does mean the board cannot rely on management's judgment about the deal in the way it does for ordinary business decisions, and it should know the terms of management's arrangements before weighing management's recommendation.
Directors with relationships to the buyer. Prior employment, other board seats, co-investments, personal ties. These need to be disclosed promptly by the director who holds them and evaluated by the rest of the board with counsel, and where a genuine conflict exists, the board has to take real steps to neutralize it rather than noting it and moving on.
The founder's attachment. Less a legal conflict than a human one, but it shapes outcomes. A founder may resist a sale that is good for shareholders because the company is their life's work, or may favor a buyer who promises to preserve the program over one who offers more value. Both impulses are understandable and neither is the standard the board is held to.
Running a Process That Holds Up
Given those conflicts, what does good practice look like? A few structural moves do most of the work, and the pattern is consistent enough that boards should treat it as a default rather than a special measure.
Constitute a genuinely independent committee where conflicts warrant it. The strength of a special committee lies entirely in whether its members are actually independent and disinterested, and whether it functions as a real decision-making body rather than a formality that ratifies what the conflicted parties wanted. Independence and disinterestedness are the strongest protections available to a board, and they are also the first thing challenged afterward. A committee whose members have their own stakes, or which defers in practice to the very directors it was formed to insulate the process from, provides no protection and creates a false sense of security.
Give the committee its own advisors. A special committee that retains independent legal counsel and its own financial advisor is in a materially stronger position than one relying on the advisors selected by management or by the conflicted investors. This is not a signal of distrust in the company's regular advisors; it is recognition that advisors have their own relationships and incentives, and that a committee needs counsel whose loyalty runs to the committee.
Test the market, and be honest about whether you actually did. A market check — a real effort to determine whether a better alternative exists — is one of the strongest indicators of a sound process. Boards get into difficulty when the check is thin: a handful of calls, a narrow outreach, a process designed to confirm the deal already in hand rather than to genuinely surface alternatives. The board should ask whether the process would have found a better offer if one existed, and should be uncomfortable if the honest answer is no.
Understand the alternatives to selling. A board evaluating an offer needs a real view of what the company is worth if it does not sell — continuing to develop, raising another round, partnering the asset, or a different transaction structure. Without that, the board cannot judge whether the offer is good; it can only judge whether it is better than nothing, which is not the same question. In a company with limited runway, this analysis is genuinely hard and genuinely essential, because runway pressure is the most common source of a bad deal accepted from a weak position.
Create a record of the reasoning. Boards under time pressure compress deliberation and document it thinly, and then find themselves years later trying to reconstruct why they did what they did. Contemporaneous minutes that reflect the actual analysis — alternatives considered, conflicts identified and how they were managed, why the board concluded what it concluded — are both a discipline that improves the decision and a record that supports it later.
The Biopharma-Specific Texture
Several features of these transactions are particular to clinical-stage life sciences and deserve specific board attention.
Much of the consideration in biopharma M&A is frequently contingent — milestone payments tied to development, regulatory, or commercial events, sometimes structured as contingent value rights. This means the headline number and the realistic number can differ substantially, and the board's job is to evaluate the risk-adjusted value rather than the announced total. The relevant questions are how achievable the milestones actually are, who controls the effort required to reach them after closing, and what obligation the buyer has to pursue them diligently. A large contingent component transfers real risk to the selling shareholders and should be discounted accordingly, not celebrated at face value.
Diligence in a biopharma transaction is unusually penetrating: the buyer will examine the clinical data, the manufacturing, the regulatory correspondence, and above all the intellectual property with a rigor the company may never have applied to itself. Boards should expect that this process can surface problems the company did not know it had — an IP gap, a data quality issue, a regulatory ambiguity — and should understand that these discoveries can reprice or break a deal. The board's interest is in knowing about such issues before the buyer finds them, which is an argument for readiness work long before a process begins.
And timing interacts with the clinical calendar in a way that is distinctive. A company approaching a significant data readout is negotiating against a known inflection point, and both sides know it. Selling before the readout transfers the risk and the upside to the buyer; waiting exposes the shareholders to the outcome. That decision is squarely the board's, it is a judgment rather than a calculation, and it should be made deliberately rather than by default of whenever the offer happened to arrive.
The Traps
Letting the process outrun the governance. Deals develop momentum, and a board can find itself approving in a compressed window a transaction whose structure was effectively set weeks earlier by management and a lead investor. The board's engagement has to begin when the process begins, not when the documents are ready for signature.
Confusing a good price with a good process. A board that secures an attractive number sometimes concludes that the process questions are academic. They are not. The two are evaluated separately, and a strong price does not cure a process in which conflicts went unmanaged.
Treating the special committee as a formality. A committee that exists on paper, meets rarely, uses the company's regular advisors, and ratifies decisions made elsewhere is worse than no committee, because it creates a false appearance of protection while providing none.
Negotiating from a runway cliff. The single most reliable cause of a disappointing outcome is a company that reaches the table with weeks of cash and no alternative. That is a governance failure that occurred months earlier, in the decisions that allowed the company to arrive there without options.
The Underlying Principle
M&A is where a board's quality becomes visible, because it is the moment when the alignment that carried the company through its building years no longer holds and the board must act for shareholders as a whole against the pull of the specific interests around the table. The investor director's fund, the executive's retention package, the founder's attachment, the divergence between preferred and common — none of these are scandals, and all of them are real.
Governing this well is largely a matter of doing unglamorous things early and deliberately: identifying the conflicts before the process gains momentum, insulating the decision from them in a way that is real rather than nominal, genuinely testing whether something better exists, understanding honestly what the company is worth if it does not sell, and recording the reasoning as it happens. A board that does those things can deliver a result it can defend — and, more importantly, one it should not need to.
This article opens the resumption of the Capital & Strategic Transactions pillar.
Lawrence Fine is CEO of AGCP Farmacêuticos and has advised on licensing, regulatory, and partnership strategy across the pharmaceutical and advanced materials sectors.